All right, so welcome back to the internet book of critical care podcast.

I'm here with Adam Thomas.

And we're going to talk today about unfractionated heparin, a little molecularoid

heparin, find the paradox of archatriban, and bivalruden.

Josh, I know everybody's probably still focused on COVID, but I think it's important

that we move on and

remember all the other things of critical care going on, just like we started with COPD

last week. But why is anticoagulation still pertinent in this day and age?

Antiquagulation is so important. If you think about it, we probably give some anticoagulant

to the vast majority of patients in the ICU if you include

prophylaxis for DVT.

So we're continually giving patients these medications.

They're potentially pretty high risk medication.

So I think it's impossible to spend too much time or to know too much about antigululants.

Sounds good to me.

So today we'll go over the basic science.

We will gently go back into the cascade.

Don't worry. We'll talk about your unfractionated heparins and your low molecular heparins. We will talk about intravenous direct thrombin inhibitors and then we'll go through all the heparin resistance protocols you need to be savvy on the warts. So go back to medical school. Josh is making me do this because I'm closer in med school than him.

Remember, we have a common pathway.

We have a contact activation pathway, which is the so-called intrinsic pathway.

And we have the tissue factor pathway, the extrinsic pathway.

Don't remember anything other than an intrinsic when there's damaged surface.

...